ME Therapeutics Added To CSE25 Index Of Largest Canadian Securities Exchange Companies

ME Therapeutics Holdings Inc. is a preclinical stage biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. The Company’s focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. The Company’s lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. This antibody drug candidate is being developed to treat colorectal cancer. In addition to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. It has also initiated design and testing of two mRNA-based cancer therapeutic drug candidates. Its lead mRNA candidates target a known…